Cargando…

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands

IMPORTANCE: The number of new cancer medicines that are being approved by regulatory agents is increasing exponentially. Yet little is known about the pace at which these medicines reach eligible patients in daily clinical practice during different phases of the postapproval access pathway. OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luyendijk, Marianne, Blommestein, Hedwig, Uyl-de Groot, Carin, Siesling, Sabine, Jager, Agnes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936344/ https://www.ncbi.nlm.nih.gov/pubmed/36795415 http://dx.doi.org/10.1001/jamanetworkopen.2022.56170

Ejemplares similares

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Changes in survival in de novo metastatic cancer in an era of new medicines
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands
por: Chen, Yi Hsuan, et al.
Publicado: (2023)

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
por: Blommestein, Hedwig M., et al.
Publicado: (2021)

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?
por: Jongbloed, Elisabeth M, et al.
Publicado: (2023)

Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review
por: Chen, Yi Hsuan, et al.
Publicado: (2022)

Approval, reimbursement and pricing of high-cost cancer medicines in Australia
por: Vitry, Agnes
Publicado: (2015)

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
por: Blommestein, Hedwig M., et al.
Publicado: (2019)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
por: Uyl-de Groot, Carin A., et al.
Publicado: (2018)

Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)
por: Verelst, Silvia G.R., et al.
Publicado: (2018)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines
por: Gold, Laura S., et al.
Publicado: (2012)

Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach
por: Clarijs, Marloes E., et al.
Publicado: (2021)

Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
por: van den Brink, Rinke
Publicado: (2014)

Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab
por: Franken, Margreet, et al.
Publicado: (2020)

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
por: De Groot, S., et al.
Publicado: (2017)

Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference?
por: Kollen, Boudewijn J, et al.
Publicado: (2012)

Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
por: Bakker, LJ, et al.
Publicado: (2023)

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks
por: van der Gronde, Toon, et al.
Publicado: (2017)

Increasing Costs of Skin Cancer due to Increasing Incidence and Introduction of Pharmaceuticals, 2007–2017
por: NOELS, Eline, et al.
Publicado: (2020)

Variation in Practice Patterns and Reimbursements Between Female and Male Urologists for Medicare Beneficiaries
por: Nam, Catherine S., et al.
Publicado: (2019)

Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
por: Herbrand, Amanda Katherina, et al.
Publicado: (2021)

Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis
por: Li, Jinming, et al.
Publicado: (2020)

Effect of reimbursement restriction policy on the use of benzodiazepines in the Netherlands: an interrupted time series analysis
por: Stoker, Lennart Jan, et al.
Publicado: (2019)

Differential Regulation of Cyclin E by Yorkie-Scalloped Signaling in Organ Development
por: Shu, Zhiqiang, et al.
Publicado: (2017)

Real‐world evidence in health technology assessment of high‐risk medical devices: Fit for purpose?
por: Klein, Philip, et al.
Publicado: (2022)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain
por: Poveda, José Luis, et al.
Publicado: (2023)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

Distinct and Overlapping Requirements for Cyclins A, B, and B3 in Drosophila Female Meiosis
por: Bourouh, Mohammed, et al.
Publicado: (2016)

Cyclin C Regulated Oxidative Stress Responsive Transcriptome in Mus musculus Embryonic Fibroblasts
por: Stieg, David C., et al.
Publicado: (2019)

Concordance of Disclosed Hospital Prices With Total Reimbursements for Hospital-Based Care Among Commercially Insured Patients in the US
por: Horný, Michal, et al.
Publicado: (2021)

Immediate Postpartum Long-Acting Reversible Contraceptive Use Following State-Specific Changes in Hospital Medicaid Reimbursement
por: Steenland, Maria W., et al.
Publicado: (2022)

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2022)

Cyclin D1 expression in prostate carcinoma
por: Pereira, R.A., et al.
Publicado: (2014)

Genetic Evidence for Roles of Yeast Mitotic Cyclins at Single-Stranded Gaps Created by DNA Replication
por: Signon, Laurence
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7mckaec6ie2v1luhbt36580bu6